PREVENTION OF DYSURIA AFTER HIFU THERAPY FOR PROSTATE CANCER

Objective: to identify factors for the development of dysuria and its prevention in patients with prostate cancer (PC) after high-intensity focused ultrasound (HIFU) therapy.

Subjects and methods. In September 2008 to June 2013, the Clinic of Urology, S.M. Kirov Military Medical Academy, treated 98 patients, by performing HIFU sessions on an Ablatherm apparatus (EDAP, France). All the patients underwent transurethral resection of the prostate (TURP) to reduce the volume of the ablated tissue. The patients were divided into 2 groups: 1) 29 patients underwent TURP 3 days before HIFU therapy; 2) 69 did this 1 month before major surgery. Each group was divided into 2 subgroups: 1) after ultrasound ablation, a urethral catheter was inserted for 10 days; 2) epicystostoma was applied, followed by its overlapping on day 3 postablation and spontaneous urination. The postoperative incidence of dysuria was estimated from subjective (complaints, voiding diary, and Inter-national Prostate Symptom Score) and objective (uroflowmetry, small pelvic ultrasonography with determination of residual urine volume) criteria.

Results. In the patients who had undergone TURP one month before HIFU therapy, grades I–II urinary incontinence and urethral pros-tatic stricture occurred much less infrequently than in those who had undergone this maneuver 3 days prior to major surgery. Urinary in-continence and urethral prostatic stricture occurred 2-fold more frequently after TURP being carried out 3 days before HIFU therapy than after the urethral catheter being inserted. TURP performed one month before HIFU therapy showed no great difference in the incidence complications regardless of the type of bladder drainage.

Conclusion. The short interval between TURP and HIFU therapy for PC increases the risk of postoperative dysuric events. The optimal time to perform TURP prior to HIFU therapy is 1 month.

1. Boyle P., Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 2005;16:481–8.

2. Чиссов В.И., Русаков И.Г. Заболевае-мость раком предстательной железы в Рос-сийской Федерации. Экспер и клин уроло-гия 2011;2–3:6–7.

3. Аполихин О.И., Сивков А.В., Бешлиев Д.А. и др. Анализ урологической заболеваемо-сти в Российской Федерации в 2002–2009 годах по данным официальной статистики. Экспер и клин урология 2011;1:4–10.

4. Potters L., Morgenstern C., Calugaru E. et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2008;179(5 Suppl):20–4.

5. Thuroff S., Chaussy C. Evolution and outcomes of 3 MHz High intensity focused ultrasound therapy for localized prostate cancer over 15 years. J Urol 2013;190(2):702–10.

6. Хаметов Р.З. Ультразвуковая абляция и брахитерапия при лечении рака предста-тельной железы. Автореф. дис. … канд. мед.наук. Саратов, 2013.

7. Шосси К. Мировой опыт HIFU-терапии РПЖ. Экспер и клин урология 2011;2–3:44–7.

8. Thuroff S., Chaussy C. High-intensity focused ultrasound: complications and adverse events. Mol Urol 2011;4:183–7.

9. Gelet A., Chapelon J.Y., Poissonnier L. et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 2004;63:625–9.

10. Dearnaley D.P., Hall E., Lawrence D. et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2011;92:488–98.